Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in
individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Background Despite the availability of effective therapies for patients with chronic kidney
disease, type 2 diabetes, and hypertension (the kidney-dysfunction triad), the results of large …

Prevention of Cardiovascular Disease in Type 1 Diabetes | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Importance Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk
in adults with type 2 diabetes are underused in clinical practice. Objective To assess the …

Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by
the American Heart Association in response to the high prevalence of metabolic and kidney …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …